Applied UV, Inc. · OTC:AUVI

Applied UV — IPO Roadshow (November 2020)

27 slides from Applied UV's IPO roadshow presentation, Nov 4, 2020

  1. Slide 1: Patent-protected Devices Addressing Global Healthcare Pathogen Crisis

    Patent - protected Devices Addressing Global Healthcare Pathogen Crisis NASDAQ:AUVI November 2020 Applied UV, Inc. Free Writing Prospectus filed pursuant to Rule 433 Registration Statement on Form S - 1 (No. 333 - 249830) November 3, 2020

  2. Slide 2: Safe Harbor Statement

    Applied UV, Inc. (NASDAQ:AUVI) This presentation may contain “forward - looking statements . ” Forward - looking statements reflect the current view about future events . When used in this prospectus, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negativ

  3. Slide 3: Offering and Information Disclaimer

    Applied UV, Inc. (NASDAQ:AUVI) This presentation highlights basic information about us and the offering. Because it is a summary that has been prepared sole ly for informational purposes, it does not contain all of the information that you should consider before investing in our company. Except as o

  4. Slide 4: Risk Factors Summary

    Applied UV, Inc. (NASDAQ:AUVI) Investing in our securities stock involves a high degree of risk . You should carefully consider the risks described below, as well as other information included in our S - 1 Registration Statement, including our financial statements and the related notes, and the sect

  5. Slide 5: Company Overview

    Applied UV, Inc. (NASDAQ:AUVI) 5 Company Overview • Our subsidiary, Munn Works, supplies mirrors and bathroom vanities to global, blue - chip hotel chains and provides SteriLumen with first - mover advantage into the hospitality sector 1. Based on estimates and non - audited financials We are curren

  6. Slide 6: Two Synergistic Companies

    Applied UV, Inc. (NASDAQ:AUVI) 6 Two Synergistic Companies Foundation Hospitality mirrors for the world’s finest hotels • Mirrors for fine hotels including the Four Seasons, Hilton, Marriott, and Hyatt • 15% CAGR during last 5 years 1 • Est. $4.6M - $5.0M revenue last nine months ended September 30,

  7. Slide 7: Joint Development and Licensing Agreement

    Applied UV, Inc. (NASDAQ:AUVI) 7 Joint Development and Licensing Agreement On October 19, 2020, we entered into a Joint Development and License Agreement with Axis Lighting Inc., one of the largest independent architectural lighting companies in North America • Axis’ new dedicated healthcare facilit

  8. Slide 8: Expansion of Airocide Relationship

    Applied UV, Inc. (NASDAQ:AUVI) 8 Expansion of Airocide Relationship Applied UV has signed a non - binding LOI to explore the possibility of acquiring the assets of Akida Holdings LLC, the manufacturer of the Airocide ™ system of patented air purification technologies originally developed for NASA, f

  9. Slide 9: Products

    Products

  10. Slide 10: Solving the Hospital Acquired Infections Problem

    Applied UV, Inc. (NASDAQ:AUVI) 10 Solving the ‘Hospital Acquired Infections’ (“HAIs”) Problem Automated disinfection system designed to neutralize HAIs on surrounding surfaces • Disinfection technology that applies the power of UVC light to destroy pathogens safely, thoroughly and automatically • Ap

  11. Slide 11: Testing and Validation

    Applied UV, Inc. (NASDAQ:AUVI) 11 Testing and Validation • Validation in active patient rooms at Mt. Sinai St. Luke’s Hospital underway • SteriLumen expects to report top line results from Mt. Sinai’s report in Q2 - 2021 • Mt. Sinai has agreed to publish their results in an academic, peer - reviewed

  12. Slide 12: Tested Against Major Bacterial Infections

    Applied UV, Inc. (NASDAQ:AUVI) • The wall - mounted mirrors with SteriLumen technology were tested for their ability to kill three healthcare - relevant bacteria: C diff, E coli and MRSA 12 Tested Against Major Bacterial Infections 0 0.5 1 1.5 2 2.5 C diff E. coli MRSA (antiobiotic resistant staph i

  13. Slide 13: Tested Against Human Coronavirus OC43

    Applied UV, Inc. (NASDAQ:AUVI) • The SteriLumen disinfecting mirror and disinfecting drain were tested at ResInnova against OC43 human coronavirus and demonstrated effectiveness in destroying the pathogen 13 Tested Against Human Coronavirus OC43 • The mirror unit demonstrated up to 99.956% destructi

  14. Slide 14: No Good Alternatives in Market

    Applied UV, Inc. (NASDAQ:AUVI) 14 No Good Alternatives in Market Performed at best every 24 hours, allowing for the possibility of recontamination Manual Disinfection UV Room Devices/Robots Hydrogen Peroxide Vapor SteriLumen Can run as needed Manpower intensive (hospitals, hotels) Expensive (~$2.5K

  15. Slide 15: Back to Normal?

    Applied UV, Inc. (NASDAQ:AUVI) 15 Back to “Normal”? • Businesses and organizations are seeking to quickly implement cost effective sanitary solutions to re - engage customers and provide basic services to the community

  16. Slide 16: Affordable and Effective Pathogen Destruction

    Applied UV, Inc. (NASDAQ:AUVI) Commercial/Residential Real Estate Government Sport/Entertainment Venues Retail Tourism 16 Affordable and Effective Pathogen Destruction • The SteriLumen provides a cost effective and fully automated disinfection solution • No human intervention necessary • MSRP $700 -

  17. Slide 17: Market Verticals & Pipeline

    Applied UV, Inc. (NASDAQ:AUVI) 17 Market Verticals & Pipeline Key Market Segments Key Metrics Healthcare/ Hospitals • HAI’s cause 99,000 Deaths/Year in US (CDC) 1 • Costs Hospitals approximately $37B/Year in US alone 2 Hospitality • Hotels currently on pace to lose up to $400M/Day in room revenue 3

  18. Slide 18: Patent Protected

    Applied UV, Inc. (NASDAQ:AUVI) 18 Patent Protected • Patents and applications cover various aspects of the SteriLumen Disinfecting Systems: • Disinfection systems embedded into fixtures, vanity mirrors, stand - alone shelves, and drainpipes • Solution designed to be retrofitted to Bank ATMs to autom

  19. Slide 19: Net Sales and EBIT

    Applied UV, Inc. (NASDAQ:AUVI) 19 Net Sales and EBIT $7.6 $9.3 $4.6 $0.0 $1.0 $2.0 $3.0 $4.0 $5.0 $6.0 $7.0 $8.0 $9.0 $10.0 2018 2019 Last 9 months Millions $0.5 $0.8 ($0.5) ($0.6) ($0.4) ($0.2) $0.0 $0.2 $0.4 $0.6 $0.8 $1.0 2018 2019 Last 9 months Millions Net Sales Net Cash Provided (Used) in Oper

  20. Slide 20: Munn Works and SteriLumen

    Munn Works and SteriLumen

  21. Slide 21: Restarting the Global Economy

    Applied UV, Inc. (NASDAQ:AUVI) 21 Restarting the Global Economy • With the emergence of COVID - 19, all public spaces and verticals become viable markets for our technology: – A fifth of human coronavirus infections among hospital patients and almost 9 in 10 infections among healthcare workers may h

  22. Slide 22: Go to Market Strategy

    Applied UV, Inc. (NASDAQ:AUVI) • Complete institutional validation with Mt. Sinai and other key influencers • Drive initial pipeline and sales with visible, high value launch customers • Attack key verticals: – Hospitality: Hotels & Casinos (Leverage MunnWorks) – Entertainment & Leisure: Travel Crui

  23. Slide 23: Financials & Capitalization

    Financials & Capitalization

  24. Slide 24: Financials and Capitalization

    Applied UV, Inc. (NASDAQ:AUVI) 24 Financials and Capitalization • Est. $6.0M of cash as of September 30, 2020 • Approx. $100,000 of debt • Est. $4.6M - $5.0M revenue for the last 9 months ended September 30, 2020 1 Common Stock Equivalents as of October 21, 2020 1 # Common Stock 6,543,129 Options (w

  25. Slide 25: Experienced Management Team

    Applied UV, Inc. (NASDAQ:AUVI) 25 Experienced Management Team • CEO Ubiquity LLC • CEO & Founder at Vital Neuro, Inc. • CSO at Kymeta Corp. • Cofounder and CxO, Open Range Communications • AT&T Wireless Advanced Services • B.S., University of Denver Keyoumars (Q) Saeed Chief Executive officer and Di

  26. Slide 26: Strong Independent Board Leadership and Capability

    Applied UV, Inc. (NASDAQ:AUVI) 26 Strong Independent Board Leadership and Capability • President, Windy City Inc. • CEO Walnut Financial: Sold to Tower Hill Capital Group in 1999 in transaction valued at $400 million • Early - stage investor at BioHorizons, Clarisonic, Encore Medical, GranCare, Heal

  27. Slide 27: Company Contact

    Company Contact: Q Saeed Chief Executive Officer 914.665.6100 q@sterilumen.com www.applieduvinc.com www.munnworks.com www.sterilumen.com NASDAQ:AUVI Investor Relations: Kevin McGrath 646.418.7002 kevin@tradigitalir.com MJ Clayburn 917.327.6847 Clyburn@tradigitalir.com Applied UV, Inc.

Applied UV — IPO Roadshow (November 2020) on 6ix